Table 1.

Baseline factors influencing degrees of uric acid reduction

Factors	β	P
Multivariate analysis for uric acid reduction at week 4
Tofogliflozin (40 mg vs 10 mg)	0.12	.19
Tofogliflozin (40 mg vs 20 mg)	0.07	.10
Sex (women)	−0.46	<.0001*
Angiotensin receptor blocker	0.13	.0034
Diuretics	0.19	.0176
Age (years)	−0.01	.0065
HbA1c (%)	0.15	<.0001*
Uric acid (mg/dL)	−0.31	<.0001*
Fasting plasma glucose (mg/dL)	0.002	.0039
Log10‐transformed urinary albumin–creatinine ratio (log10 mg/g Cr)	0.07	<.0001*
Log10‐transformed urinary NAG–creatinine ratio (log10 U/g Cr)	0.19	<.0001*
eGFR (mL/min/1.73 m2)	−0.01	<.0001*
Multivariate analysis for uric acid reduction at week 24
Tofogliflozin (40 mg vs 10 mg)	0.10	.3458
Tofogliflozin (40 mg vs 20 mg)	−0.004	.93
Sex (women)	−0.56	<.0001*
Angiotensin receptor blocker	0.13	.0137
Diuretics	0.27	.0038
Body mass index (kg/m2)	0.02	.0006
HbA1c (%)	0.21	<.0001*
Homeostatic model assessment of insulin resistance	0.005	.0116
Uric acid (mg/dL)	−0.3	<.0001*
Log10‐transformed urinary albumin–creatinine ratio (log10 mg/g Cr)	0.05	.0093
Log10‐transformed urinary NAG–creatinine ratio (log10 U/g Cr)	0.2	<.0001*
eGFR (mL/min/1.73m2)	−0.003	.0427

Selected factors for the multivariate analysis: dosage of tofogliflozin, age, sex, duration of diabetes, glycosylated hemoglobin (HbA1c), fasting plasma glucose, glycoalbumin, homeostatic model assessment of insulin resistance, homeostatic model assessment of β cell function, systolic blood pressure, body mass index, log₁₀‐transformed urinary albumin–creatinine ratio, log₁₀‐transformed β2 microglobulin–creatinine ratio, log₁₀‐transformed N‐acetyl‐β‐D‐glucosaminidase (NAG)–creatinine ratio, estimated glomerular filtration rate (eGFR), statin, angiotensin receptor blocker, calcium channel blocker, diuretics, antihypertensive drugs, antihyperuricemic drugs, uric acid.

^* P < .0001.